PT-141 (Bremelanotide) (Vyleesi) 10mg

Description

Introduction: The FDA-Approved Sexual Function Peptide

PT-141, known generically as bremelanotide and commercially as Vyleesi, represents a revolutionary breakthrough in sexual function research. As the first and only FDA-approved melanocortin receptor agonist for sexual dysfunction, this peptide has transformed our grasp of how the brain regulates sexual desire, arousal, and performance. Unlike traditional erectile dysfunction drugs that work peripherally on blood vessels, PT-141 operates through central nervous system pathways, starting sexual arousal and desire at their neurological source.

The story of PT-141 begins with Melanotan 2, a peptide originally developed for sunless tanning that unexpectedly produced powerful pro-sexual effects in early research. Scientists recognized this serendipitous discovery’s possible and refined the compound, creating bremelanotide—a metabolite optimized mainly for sexual function boost while minimizing other effects. After over 15 years of clinical growth, PT-141 achieved FDA approval in June 2019 as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women, validating its safety and effect through rigorous Phase 3 trials.

Today, PT-141 serves as an invaluable research tool for studying sexual dysfunction in both men and women. Clinical evidence shows notable effectiveness for erectile dysfunction, very in men who don’t respond to standard PDE5 inhibitors like Viagra or Cialis. Research shows 85% of men with ED experience improved erections with PT-141, with average erection durations of 41 minutes. For women, the FDA approval confirms PT-141’s power to enhance sexual desire, arousal, and satisfaction. Perhaps most importantly, PT-141 addresses the psychological and emotional components of sexual function—reducing performance anxiety, increasing confidence, and improving overall sexual satisfaction for both partners.

PrymaLab’s PT-141 (Bremelanotide) 10mg peptide represents pharmaceutical-grade quality for serious research uses. Each vial contains 99% pure bremelanotide, verified through rigorous third-party testing using high-performance liquid chromatography (HPLC) and mass spectrometry. This exceptional purity ensures consistent, reliable results across experimental protocols. Whether studying erectile dysfunction mechanisms, exploring female sexual arousal pathways, or studying the neurobiology of desire, researchers need the highest quality peptides to create meaningful data. Our commitment to quality control and transparency makes PrymaLab the trusted source for PT-141 research.

Understanding PT-141: From Melanotan 2 to FDA-Approved Bremelanotide

PT-141’s growth represents one of the most fascinating stories in peptide research, beginning with an unexpected discovery and culminating in FDA approval. Grasp this journey provides crucial context for researchers working with this compound.

The Melanotan 2 Connection: In the 1980s, researchers at the University of Arizona developed Melanotan 2 (MT-2) as a synthetic analog of alpha-melanocyte-boosting hormone (α-MSH) for sunless tanning. The peptide successfully boosted melanin production, but early clinical trials revealed an unexpected side effect: participants reported spontaneous erections and dramatically increased sexual desire. Rather than viewing this as a problem, researchers recognized a possible breakthrough for treating sexual dysfunction.

Refinement to Bremelanotide: Scientists isolated and refined the active metabolite responsible for MT-2’s sexual effects, creating bremelanotide (PT-141). This refinement process optimized the peptide’s structure to maximize sexual function benefits while minimizing other effects like skin pigmentation. The result was a cyclic heptapeptide (seven amino acids arranged in a ring) with enhanced selectivity for sexual function pathways.

Clinical Growth Timeline:

• 2003: PT-141 first described in scientific literature as an investigational melanocortin agonist
• 2005-2007: Phase 2 trials in men with erectile dysfunction, including PDE5 inhibitor non-responders
• 2008: Shift from intranasal to under-skin form due to blood pressure concerns
• 2010-2016: Phase 3 trials in women with HSDD (RECONNECT studies)
• 2019: FDA approval as Vyleesi for female HSDD
• 2024-Present: Ongoing Phase 2/3 trials for male erectile dysfunction sign

FDA Approval Significance: The FDA approval of PT-141 as Vyleesi represents a watershed moment in sexual medicine. It’s the first centrally-acting medication approved for sexual dysfunction, validating the melanocortin receptor pathway as a legitimate treatment target. The approval was based on two Phase 3 trials (RECONNECT 1 and 2) involving over 1,200 premenopausal women with HSDD, showing statistically major gains in sexual desire and distress reduction compared to placebo.

Current Research Status: While FDA-approved for women, PT-141 research continues actively in male populations. Palatin Technologies (the developer) launched Phase 2 trials in 2024 testing bremelanotide alone and in mix with PDE5 inhibitors for male erectile dysfunction. Early results show promising effect, with plans for Phase 3 trials in 2025. Also, extensive off-label clinical use in men has created real-world evidence supporting PT-141’s effectiveness for male sexual dysfunction.

PT-141 vs Melanotan 2: Key Differences: Grasp the distinctions between PT-141 and its parent compound Melanotan 2 is essential for researchers:

1. Control Status: PT-141 has FDA approval (as Vyleesi) with set up safety profile; MT-2 remains research-only
2. Main Effects: PT-141 optimized for sexual function with minimal tanning; MT-2 produces both tanning and sexual effects
3. Receptor Selectivity: PT-141 shows higher selectivity for MC4R (sexual function); MT-2 starts MC1R, MC3R, MC4R more equally
4. Safety Profile: PT-141 has lower heart effects and better-characterized safety data from FDA trials
5. Dosing: PT-141 standard dose is 1.75mg under-skin; MT-2 dosing ranges from 0.25-2mg depending on use
6. Side Effects: PT-141 mainly causes nausea and flushing; MT-2 also causes major skin darkening
7. Clinical Evidence: PT-141 has extensive Phase 3 trial data; MT-2 has mainly Phase 1-2 data

For researchers mainly interested in sexual function without tanning effects, PT-141 is the superior choice. For studies needing multi-receptor start or examining melanogenesis alongside sexual effects, MT-2 may be more appropriate.

Molecular Structure and Mechanism of Action

PT-141’s effectiveness stems from its advanced cell-level architecture and unique mechanism of action through central nervous system pathways. Grasp these fundamentals is crucial for researchers designing experimental protocols.

Chemical Structure: PT-141 (Bremelanotide) is a cyclic heptapeptide with the sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. Key structural features include:

• Cyclic Configuration: Seven amino acids arranged in a ring through a lactam bridge between aspartic acid (position 2) and lysine (position 7)
• Cell-level Formula: C50H68N14O10
• Cell-level Weight: 1025.2 g/mol
• D-Amino Acid: Contains D-phenylalanine (unnatural amino acid) at position 4, enhancing shelf life
• N-terminal Change: Acetylated norleucine at position 1 improves lipophilicity

Structural Benefits: The cyclic structure provides several key benefits over linear peptides:

1. Body Shelf life: Ring formation protects against enzymatic breakdown by peptidases, extending half-life to 2.7 hours (vs. 1-2 hours for linear analogs)
2. Enhanced Receptor Binding: Constrained structure positions amino acids optimally for melanocortin receptor interaction
3. Improved Uptake: 100% uptake via under-skin injection
4. Reduced Side Effects: Optimized structure minimizes off-target effects compared to parent compound MT-2

Melanocortin Receptor System: PT-141 exerts its effects by starting melanocortin receptors, a family of G-protein coupled receptors (GPCRs) that regulate diverse natural functions. The five melanocortin receptor subtypes and PT-141’s affinity for each (in order of potency):

1. MC1R (Melanocortin-1 Receptor): Highest affinity – Regulates melanogenesis and skin pigmentation
2. MC4R (Melanocortin-4 Receptor): High affinity – Mediates sexual function, arousal, and erectile response
3. MC3R (Melanocortin-3 Receptor): Moderate affinity – Regulates energy homeostasis and appetite
4. MC5R (Melanocortin-5 Receptor): Moderate affinity – Involved in exocrine gland function
5. MC2R (ACTH Receptor): Low affinity – Regulates adrenal steroid production

Central Mechanism for Sexual Function: PT-141’s pro-sexual effects mainly result from MC4R start in the central nervous system, very in the hypothalamus. The mechanism unfolds through several interconnected pathways:

Step 1: Hypothalamic Start After under-skin injection, PT-141 crosses the blood-brain barrier and binds to MC4R receptors in the paraventricular nucleus (PVN) of the hypothalamus. The PVN serves as a key integration center for sexual function, getting inputs from multiple brain regions and coordinating sexual responses.

Step 2: Dopamine Release MC4R start in the PVN triggers increased dopamine release in the medial preoptic area (MPOA), a brain region that governs sexual motivation and desire. Dopamine is the main neurotransmitter linked with sexual excitement, reward, and pleasure. This dopaminergic surge creates the subjective feeling of sexual desire and interest.

Step 3: Oxytocin Pathway MC4R start also boosts oxytocin neurons in the PVN. Oxytocin plays crucial roles in sexual arousal, pair bonding, and orgasm. These oxytocin neurons project to the spinal cord, where they help erectile reflexes through parasympathetic start.

Step 4: Spinal Cord Signaling Neural signals travel from the hypothalamus down the spinal cord to the sacral parasympathetic nuclei. These nuclei control the pelvic nerves that innervate erectile tissue in both males and females. Start of these pathways starts the natural processes of erection and genital engorgement.

Step 5: Peripheral Effects While PT-141 mainly works centrally, some peripheral effects occur through melanocortin receptor start in genital tissues. These local effects may enhance response and blood flow, complementing the central arousal signals.

Key Mechanistic Distinctions: PT-141’s central mechanism fundamentally differs from peripheral erectile dysfunction treatments:

• PDE5 Inhibitors (Viagra, Cialis): Work peripherally by blocking phosphodiesterase-5 in penile blood vessels, enhancing blood flow in response to sexual boost. They help erections but don’t create desire or arousal.
• PT-141: Works centrally by starting brain pathways that create sexual desire and start arousal. It can produce erections even without deliberate sexual boost by triggering the body’s natural arousal cascade.

This central mechanism explains several unique PT-141 characteristics:

1. Effectiveness for both erectile dysfunction AND low libido
2. Power to help PDE5 inhibitor non-responders
3. Reduction in performance anxiety
4. Boost of subjective sexual experience and satisfaction
5. Effectiveness in both men and women

Pharmacokinetics: Grasp PT-141’s pharmacokinetic profile helps researchers optimize dosing protocols:

• Absorption: 100% bioavailable via under-skin injection
• Tmax (Time to Peak): 1.0 hour (range: 0.5-1.0 hours)
• Cmax (Peak Level): 72.8 ng/mL
• Volume of Distribution: 25.0 ± 5.8 L
• Protein Binding: 21% bound to serum proteins
• Body function: Hydrolysis of peptide bonds (no hepatic body function)
• Half-Life: 2.7 hours (range: 1.9-4.0 hours)
• Clearance: 6.5 ± 1.0 L/hr
• Excretion: 64.8% in urine, 22.8% in feces

Duration of Action: While the half-life is 2.7 hours, PT-141’s effects on sexual function persist longer:

• Onset: 30-60 minutes post-injection
• Peak Effects: 1-2 hours post-injection
• Duration: 6-12 hours of enhanced sexual responsiveness
• Residual Effects: Some users report mild effects up to 24 hours

This extended duration of action relative to half-life suggests that PT-141’s effects involve neuroplastic changes or sustained receptor start that outlast the peptide’s presence in circulation.

Clinical Evidence: Comprehensive Research Overview

PT-141’s clinical growth spans over 15 years with extensive research in both male and female populations. This section synthesizes key findings from clinical trials, real-world studies, and ongoing research.

Phase 2 Trials in Men with Erectile Dysfunction (2005-2007):

The first clinical trials of PT-141 in men used an intranasal spray form. These studies provided the first human evidence of PT-141’s effectiveness for male sexual dysfunction.

Large Multi-Center Trial (2007):

• Design: Randomized, placebo-controlled trial presented at American Urological Association meeting
• Population: 726 men with erectile dysfunction, average age 55
• Intervention: Intranasal PT-141 at doses ranging from 5mg to 15mg, gave 45 minutes before sexual activity
• Duration: 12 weeks
• Key Findings:
  • Doses of 7.5mg and above produced statistically major gains in IIEF (International Index of Erectile Function) scores vs placebo
  • Dose-dependent effect saw, with higher doses yielding better erectile function
  • Major gains in Self-Esteem and Relationship (SEAR) scores, showing enhanced sexual confidence and relationship satisfaction
  • Dr. Stanley Althof (lead investigator) noted meaningful gains in psychosocial aspects of sexual function, not just physical erections

Sildenafil Non-Responder Trial (Safarinejad et al., 2008):

• Design: Randomized, double-blind, placebo-controlled study published in Journal of Urology
• Population: 342 men with ED who had failed sildenafil (Viagra) treatment
• Intervention: Intranasal PT-141 10mg vs placebo, on-demand over 4-8 weeks
• Key Findings:
  • 33.5% of PT-141 users achieved positive clinical response (erections enough for intercourse) vs 8.5% on placebo (p=0.03)
  • Major gains in intercourse satisfaction and successful coitus episodes
  • Showed PT-141’s possible as “salvage therapy” for PDE5 inhibitor non-responders
  • Authors concluded PT-141 could serve “a possibly broad patient base”

Mix Therapy Study (2005):

• Design: Exploratory study using RigiScan objective measurement
• Population: 32 men with erectile dysfunction
• Intervention: Intranasal PT-141 (7.5 or 10mg) + oral sildenafil (50 or 100mg) vs sildenafil alone
• Measurement: RigiScan device objectively measured erectile rigidity over 6 hours
• Key Findings:
  • Mix therapy increased duration of erectile activity by 5.3-fold vs sildenafil alone
  • Statistically major boost in most dose comparisons
  • No serious adverse events with mix
  • Showed powerful synergy: PT-141 starts arousal centrally while sildenafil enhances vascular response

Phase 3 Trials in Women with HSDD (RECONNECT Studies):

The pivotal trials that led to FDA approval provide the most robust clinical evidence for PT-141’s effect and safety.

RECONNECT 1 and 2 (2016-2018):

• Design: Two identical Phase 3, randomized, double-blind, placebo-controlled trials
• Population: 1,247 premenopausal women with got, generalized HSDD
• Intervention: Under-skin bremelanotide 1.75mg vs placebo, self-gave as needed before sexual activity
• Duration: 24 weeks
• Main Endpoints:
  1. Change in sexual desire (measured by eDiary)
  2. Change in distress related to low sexual desire (measured by FSDS-DAO)
• Key Findings:
  • Statistically major gains in both main endpoints vs placebo in both trials
  • Mean increase in satisfying sexual events per month
  • Gains kept throughout 24-week study period
  • Favorable safety profile with mainly transient side effects
  • Led to FDA approval in June 2019

Real-World Clinical Experience (Goldstein & Goldstein, 2024):

Recent observational data from specialized sexual medicine clinics provides valuable real-world evidence of PT-141’s effectiveness in men.

Study Design:

• Population: 21 men with many sexual dysfunctions (low libido, ED, orgasm difficulties)
• Intervention: Under-skin bremelanotide 1.75mg, self-gave as needed
• Setting: Off-label use in clinical practice
• Assessment: Patient-reported outcomes after minimum 2 doses

Key Findings:

• Patient Satisfaction: 80% reported being more satisfied with lovemaking experience and duration
• Sexual Pleasure: 70% said sex was more pleasurable for both themselves and partner
• Confidence: 86% felt more at ease starting intimacy
• Specific Gains:
  • 39% gain in low sexual desire (male HSDD)
  • 52% gain in erectile dysfunction symptoms
  • 17% gain in difficulty achieving orgasm
• Global Gain: 53-70% rated sexual function as “a little better” to “very much better” on PGI-I scale
• Adherence: 73% refill rate over 18 months, showing sustained perceived benefit
• Comparison: Men had much higher refill rates than women (73% vs 29-52%), suggesting very strong effect in male population

Ongoing Phase 2 Trial (2024-Present):

Palatin Technologies started a Phase 2 open-label trial in 2024 testing PT-141 in men with ED who are PDE5 inhibitor non-responders.

Study Details:

• Population: 50 men with ED inadequately responsive to PDE5 inhibitors
• Intervention: Bremelanotide co-formulated with a PDE5 inhibitor in single injection
• Objectives: Optimize dosing, assess safety/effect of mix approach
• Timeline: Topline results expected end of 2024, with Phase 3 planned for 2025
• Rationale: Addresses large unmet need (~40% of ED patients don’t respond adequately to PDE5 inhibitors alone)

Clinical Evidence Summary:

The totality of clinical evidence shows:

1. Effect in Male ED: 33-85% response rates depending on population and outcome measures
2. Effectiveness for PDE5i Non-Responders: Major benefit in men who failed standard ED treatments
3. Libido Boost: Gains in sexual desire for both men and women
4. Mix Synergy: 5-fold boost when combined with PDE5 inhibitors
5. FDA Validation: Approval for female HSDD confirms safety and effect through rigorous Phase 3 trials
6. Real-World Effectiveness: High patient satisfaction and adherence rates in clinical practice
7. Broad Applicability: Benefits across multiple sexual dysfunction domains (desire, arousal, erection, satisfaction)

Comprehensive Dosing Protocols for Research Applications

Proper dosing represents a key factor in PT-141 research success. The peptide’s effects are highly dose-dependent, and different uses may need distinct dosing strategies. This section provides evidence-based protocols for many research objectives.

FDA-Approved Dosing (Vyleesi for Female HSDD):

The FDA-approved protocol serves as the foundation for PT-141 dosing:

• Dose: 1.75mg under-skin injection
• Timing: Give at least 45 minutes before expected sexual activity
• Frequency: As needed (PRN), maximum one dose per 24 hours
• Maximum Monthly Use: No more than 8 doses per month
• Route: Under-skin injection into abdomen or thigh
• Form: Supplied as single-use autoinjector pen

Male Erectile Dysfunction Research Protocol:

Based on clinical trials and off-label clinical experience:

• Dose: 1.75mg under-skin injection (standard)
• Other Dosing: Some clinicians use 1.25-2.0mg based on personal response
• Timing: 30-60 minutes before expected sexual activity
• Frequency: As needed, minimum 24-hour interval between doses
• Maximum Frequency: Up to 4 doses per month first, may increase to 8 doses per month if well-tolerated
• Duration: Single-dose studies or repeated dosing over 4-12 weeks
• Rationale: Higher doses (1.75-2mg) needed for reliable erectile effects in men vs women

Male Low Libido (HSDD) Research Protocol:

For studies examining sexual desire boost in men:

• Dose: 1.75mg under-skin injection
• Timing: 45-60 minutes before expected sexual activity
• Frequency: As needed, 2-3 times per week
• Duration: 8-12 weeks to assess sustained effects on desire
• Assessment: Use Sexual Desire Inventory (SDI) and Patient Global Impression of Gain (PGI-I)
• Rationale: Central mechanism addresses psychological component of low desire

Mix Therapy Protocol (PT-141 + PDE5 Inhibitor):

For research examining combined effects:

• PT-141 Dose: 1.75mg under-skin injection
• PDE5i Dose: Standard dose (e.g., sildenafil 50-100mg, tadalafil 10-20mg)
• Timing: Give both 45-60 minutes before sexual activity
• Frequency: As needed, maximum once per 24 hours
• Safety Tracking: Close tracking of blood pressure and heart parameters
• Rationale: PT-141 starts central arousal while PDE5i enhances peripheral vascular response

Mixing Instructions:

PT-141 is supplied as freeze-dried powder needing mixing before use:

Standard Mixing (for 1.75mg doses):

1. Remove flip-top cap from PT-141 vial and wipe rubber stopper with alcohol swab
2. Remove cap from sterile water vial and wipe rubber stopper with alcohol
3. Draw 2mL of sterile water into sterile syringe
4. Inject water slowly into PT-141 vial, aiming at vial wall (not directly at powder)
5. Gently swirl or tilt vial to dissolve powder (do not shake vigorously)
6. Refrigerate for 2-4 hours or overnight until completely dissolved
7. Store mixed solution at 2-8°C (refrigerated) for up to 30 days

Dosage Calculations:

For a 10mg vial mixed with 2mL sterile water:

• Level: 5mg/mL
• 1.75mg dose: 0.35mL = 35 units on 100-unit insulin syringe
• 1.5mg dose: 0.30mL = 30 units on 100-unit insulin syringe
• 1.25mg dose: 0.25mL = 25 units on 100-unit insulin syringe
• 2.0mg dose: 0.40mL = 40 units on 100-unit insulin syringe

Use Technique:

Proper injection technique ensures best absorption and minimizes side effects:

1. Syringe Selection: Use insulin syringes (0.5mL or 1mL with 29-31 gauge needles)
2. Injection Site: Abdomen (2 inches from navel) or front/outer thigh
3. Site Preparation: Clean injection site with alcohol swab, allow to dry
4. Injection Method:
   • Pinch skin to create fold
   • Insert needle at 90-degree angle (perpendicular to skin)
   • Inject slowly over 5-10 seconds
   • Remove needle and apply gentle pressure (do not rub)
5. Site Rotation: Rotate injection sites to prevent tissue irritation
6. Disposal: Dispose of needles properly in sharps container

Timing Tuning:

Maximizing PT-141 effectiveness needs proper timing:

• Onset of Action: 30-60 minutes post-injection
• Peak Effects: 1-2 hours post-injection
• Duration: 6-12 hours of enhanced sexual responsiveness
• Planning: Give 45 minutes before expected sexual activity
• Flexibility: Effects persist for several hours, allowing spontaneity within window

Food and Alcohol Factors:

• Food: PT-141 can be taken with or without food (food does not affect absorption)
• Nausea Care: Some users prefer empty stomach to reduce nausea, others find light food helpful
• Alcohol: No major interaction with alcohol (unlike flibanserin), but moderation advised as alcohol can independently affect sexual function

Dose Titration Strategy:

For subjects new to PT-141, consider gradual introduction:

Week 1-2: Start with 1.5mg to assess tolerance Week 3-4: Increase to standard 1.75mg if well-tolerated Week 5+: May increase to 2.0mg if needed for best effect (off-label)

Special Population Factors:

• Elderly Subjects: Start at lower end of dosing range (1.5mg) due to possible increased response
• Heart Concerns: Use lowest effective dose and track blood pressure closely
• Mix Therapy: Consider reducing personal doses by 25% when combining with other treatments
• Frequent Users: Track for tolerance growth; may need dose adjustment after 3-6 months

Dosing Frequency Rules:

• First Research Phase: 1-2 doses per week for 4-8 weeks to set up baseline response
• Maintenance Phase: As needed, often 2-4 times per month
• Maximum Frequency: 8 doses per month (per FDA rules)
• Minimum Interval: 24 hours between doses
• Long-term Use: Periodic washout periods (1-2 weeks every 3 months) may help keep effect

Storage and Handling:

• Freeze-dried Powder: Store at -20°C (freezer) for up to 2 years
• Mixed Solution: Store at 2-8°C (refrigerator) for up to 30 days
• Protection: Keep away from light, heat, and repeated freeze-thaw cycles
• Sterile Technique: Use proper aseptic technique to prevent contamination
• Visual Inspection: Discard if solution appears cloudy, discolored, or contains particles

Strategic Stacking Protocols and Peptide Combinations

While PT-141 shows major effects as monotherapy, strategic mixes with paired compounds can enhance specific research outcomes or provide combined benefits. This section explores evidence-based stacking protocols.

PT-141 + PDE5 Inhibitors (Viagra, Cialis, Levitra):

The most extensively studied and clinically relevant mix.

Rationale:

• PT-141 works centrally (brain) to start arousal and desire
• PDE5 inhibitors work peripherally (blood vessels) to enhance erectile rigidity
• Paired mechanisms address both psychological and vascular components of ED

Protocol:

• PT-141: 1.75mg under-skin, 45 minutes before activity
• Sildenafil: 50-100mg oral, 45-60 minutes before activity
• OR Tadalafil: 10-20mg oral, 45-60 minutes before activity
• Timing: Give both simultaneously for peak effects at same time

Evidence:

• 5.3-fold increase in erectile activity duration vs sildenafil alone
• Very effective for PDE5 inhibitor partial responders
• No serious adverse events in mix studies
• Ongoing Phase 2 trial testing co-formulated mix

Tracking:

• Blood pressure before and after dosing
• Heart parameters
• Priapism risk (though rare, mix may increase)

PT-141 + Testosterone Replacement Therapy:

For men with hypogonadism and sexual dysfunction.

Rationale:

• Testosterone provides hormonal foundation for libido
• PT-141 provides neurological start of sexual pathways
• Addresses both hormonal and neurological components

Protocol:

• Testosterone: Per standard TRT protocol (varies by form)
• PT-141: 1.75mg under-skin as needed for sexual activity
• Duration: Minimum 8-12 weeks to allow testosterone levels to stabilize

Combined Effects:

• Enhanced libido beyond testosterone alone
• Improved erectile function
• Better overall sexual satisfaction
• Reduced performance anxiety

Factors:

• Set up stable testosterone levels before adding PT-141
• Track both testosterone levels and sexual function parameters
• PT-141 does not increase testosterone (common misconception)

PT-141 + Melanotan 2:

For research examining combined sexual function and tanning effects.

Rationale:

• PT-141 optimized for sexual function
• MT-2 provides both sexual and tanning effects
• May offer enhanced sexual benefits with controlled tanning

Protocol:

• PT-141: 1.75mg under-skin for sexual activity
• MT-2: 0.25-0.5mg daily for tanning (separate from PT-141 dosing)
• Timing: Separate use by 12+ hours when possible

Factors:

• Additive side effects (nausea, flushing)
• Increased melanocortin receptor start
• Track for skin hyperpigmentation
• Not recommended for routine use; mainly for specific research objectives

PT-141 + BPC-157:

For research on sexual function healing after injury or surgery.

Rationale:

• PT-141 enhances sexual function
• BPC-157 promotes tissue healing and nerve regrowth
• May benefit post-prostatectomy or pelvic injury healing

Protocol:

• PT-141: 1.75mg under-skin as needed for sexual activity
• BPC-157: 250-500mcg twice daily, continuous
• Duration: 4-8 weeks for tissue healing effects

Uses:

• Post-surgical sexual function healing
• Pelvic nerve injury rehabilitation
• Peyronie’s disease research
• General sexual function tuning

PT-141 + Ipamorelin or Sermorelin:

For research on sexual function in aging populations.

Rationale:

• Growth hormone peptides improve overall vitality and body makeup
• PT-141 directly enhances sexual function
• May address age-related sexual decline through multiple pathways

Protocol:

• PT-141: 1.75mg under-skin as needed for sexual activity
• Ipamorelin: 200-300mcg twice daily OR
• Sermorelin: 200-300mcg daily before bed
• Duration: 12-24 weeks for full assessment

Expected Benefits:

• Enhanced sexual function from PT-141
• Improved energy and vitality from GH peptides
• Better body makeup supporting sexual confidence
• Possible combined effects on libido

PT-141 + TB-500:

For research on vascular health and sexual function.

Rationale:

• PT-141 starts central arousal
• TB-500 promotes angiogenesis and vascular health
• May enhance erectile tissue blood flow

Protocol:

• PT-141: 1.75mg under-skin as needed
• TB-500: 2-5mg twice weekly
• Duration: 6-8 weeks

Uses:

• Vascular erectile dysfunction research
• Diabetic sexual dysfunction studies
• Age-related vascular decline

Important Stacking Factors:

1. Side Effect Care:

• Combining peptides increases complexity of side effect attribution
• Introduce peptides sequentially when possible
• Set up baseline response to each compound before combining
• Track for additive or combined side effects

2. Dose Adjustments:

• Consider reducing personal doses by 25% when first combining
• Titrate upward based on response and tolerability
• Some mixes may allow lower PT-141 doses while keeping effect

3. Injection Site Care:

• Multiple daily injections need careful site rotation
• Use different anatomical areas for different peptides when possible
• Track for injection site reactions or tissue irritation

4. Timing Tuning:

• Consider pharmacokinetic profiles when scheduling injections
• Space injections by 2-4 hours when possible for independent assessment
• For sexual activity, coordinate timing for peak effects

5. Research Records:

• Keep detailed records of all peptides, doses, timing, and effects
• Document any interactions or unexpected responses
• Track effect of mix vs personal compounds

6. Safety Tracking:

• Regular blood pressure tracking (especially with PDE5i mixes)
• Heart parameter assessment
• Periodic laboratory testing as appropriate
• Watch for signs of priapism with erectile function mixes

7. Control Compliance:

• Ensure all peptides used in mixes are approved for research
• Follow institutional rules for multi-compound protocols
• Keep proper records for research oversight

Safety Profile, Side Effects, and Risk Mitigation

Grasp PT-141’s safety profile is essential for responsible research conduct. While the peptide has FDA approval with well-characterized safety data, researchers must remain aware of possible adverse effects and use appropriate tracking strategies.

Common Side Effects (Frequency >10%):

Nausea (40%):

• Most frequent side effect in clinical trials
• Often occurs 30-60 minutes post-injection
• Usually lasts 1-4 hours
• Often diminishes with repeated use (tolerance growth)
• About 13% need anti-emetic medication

Mitigation Strategies:

• Start with lower doses (1.5mg) for first 1-2 uses
• Take on relatively empty stomach (heavy meals may worsen)
• Pre-medicate with ginger, vitamin B6, or prescription anti-emetics
• Give in evening so nausea occurs during sleep
• Stay well-hydrated
• Lie down if feeling queasy

Flushing (20%):

• Facial redness and warmth
• Related to melanocortin receptor effects on blood vessels
• Usually transient (30-60 minutes)
• Often harmless

Mitigation Strategies:

• Avoid hot environments immediately post-injection
• Stay hydrated
• Use cool compresses if uncomfortable
• Often resolves without intervention

Headache (11-12%):

• Mild to moderate intensity
• May be related to blood pressure changes or flushing

Mitigation Strategies:

• Keep good hydration
• Use mild analgesics (acetaminophen) if needed
• Track blood pressure
• Report severe headaches to healthcare provider

Injection Site Reactions (5%):

• Mild pain, redness, or itching at injection site
• Usually resolves within hours

Mitigation Strategies:

• Rotate injection sites
• Use proper technique
• Ensure solution is at room heat before injecting
• Apply ice if swelling occurs

Uncommon Side Effects (Frequency 1-10%):

Spontaneous Erections (13% in men):

• Erections occurring without deliberate sexual boost
• Can be intermittent over 12-24 hours post-injection
• Related to central arousal mechanism

Care:

• Inform subjects this is expected effect
• Schedule dosing during private time
• True priapism (>4 hours continuous) is very rare but needs immediate medical attention

Skin Hyperpigmentation (1%):

• Darkening of skin, gums, or existing moles
• Due to MC1R start
• More common with frequent use (>8 doses/month)
• May not fully reverse after discontinuation in ~50% of cases

Risk Mitigation:

• Limit dosing frequency to recommended maximum
• Document baseline skin appearance and moles
• Track for new or changing pigmented lesions
• Consider dermatological evaluation for high-risk subjects

Decreased Appetite:

• Mild appetite suppression
• Related to MC3R/MC4R start
• Usually transient

Heart Effects:

Blood Pressure Changes:

• Transient increase: +2-3 mmHg systolic, +1-2 mmHg diastolic
• Slight decrease in heart rate: -2 beats per minute
• Changes peak within first hour, return to baseline within 12 hours

Clinical Significance:

• Often minimal in healthy subjects
• Possibly problematic in uncontrolled hypertension or heart disease
• Much less pronounced than intranasal form

Tracking Protocol:

• Measure baseline blood pressure
• Check BP 30-60 minutes post-injection (first few doses)
• Track for symptoms: chest pain, severe headache, vision changes
• Discontinue if BP >160/100 or major symptoms occur

Contraindications:

PT-141 should not be used in subjects with:

1. Uncontrolled Hypertension: BP >140/90 despite medication
2. Heart Disease:
   • Recent heart attack or stroke (<6 months)
   • Unstable angina
   • Severe heart failure
   • Major arrhythmias
3. Pregnancy or Breastfeeding: No safety data in these populations
4. Age <18 Years: Not studied in pediatric populations
5. Known Hypersensitivity: To bremelanotide or any component

Relative Contraindications (Use with Caution):

• Well-controlled hypertension (close tracking needed)
• History of melanoma or multiple atypical moles
• Severe renal or hepatic impairment
• History of priapism
• Concurrent use of multiple vasoactive drugs

Drug Interactions:

Naltrexone:

• PT-141 greatly reduces oral naltrexone absorption
• Separate use by 2+ hours if both needed
• Track naltrexone effectiveness

Other Drugs:

• No major interactions with PDE5 inhibitors (can be combined safely)
• No interaction with alcohol (unlike flibanserin)
• Theoretical concerns with other sympathomimetics (track BP)
• May affect absorption of oral drugs due to delayed gastric emptying

Long-Term Safety Factors:

FDA Approval Data (Up to 12 Months):

• No buildup of heart effects with ongoing use
• Blood pressure and heart rate effects remain transient
• No evidence of tissue changes or organ toxicity
• Safety profile consistent across study duration

Areas Needing Further Research:

• Effects of very long-term use (>1 year)
• Safety in special populations (elderly, multiple comorbidities)
• Long-term effects of frequent use (>8 doses/month)
• Possible for tolerance or dependence

Priapism Risk:

While rare, priapism (erection >4 hours) is a medical emergency:

Risk Factors:

• Doses >2mg
• Mix with PDE5 inhibitors or penile injections
• History of priapism or sickle cell disease
• Concurrent use of multiple pro-erectile treatments

Prevention:

• Use recommended doses
• Educate subjects on priapism recognition
• Provide clear instructions for seeking emergency care
• Consider excluding high-risk subjects

Care:

• If erection >4 hours: Seek immediate medical attention
• Treatment may include aspiration, irrigation, or sympathomimetic injection
• Delayed treatment can cause permanent erectile dysfunction

Melanoma and Skin Cancer Concerns:

Some case reports have linked melanocortin agonists to melanoma, though causation is unproven:

Risk Mitigation:

• Screen for personal/family history of melanoma
• Document baseline moles and pigmented lesions
• Limit study duration and dosing frequency
• Avoid combining with too much UV exposure
• Perform periodic dermatological examinations
• Educate subjects on melanoma warning signs (ABCDE criteria)

Pregnancy and Fertility Safety:

• Pregnancy Category: Not assigned (peptide not approved for use in pregnancy)
• Animal Studies: No enough fertility toxicity studies
• Human Data: No data on pregnancy outcomes
• Recommendation: Exclude pregnant women; use contraception during research

Quality and Purity Factors:

Peptide quality greatly impacts safety:

• Contaminants: Low-purity peptides may contain bacterial endotoxins, heavy metals, or synthesis byproducts
• Breakdown Products: Improperly stored peptides may degrade into possibly harmful compounds
• Incorrect Sequences: Poor synthesis can result in peptides with wrong amino acid sequences

PrymaLab Quality Assurance:

• 99%+ purity via HPLC
• <1 EU/mg endotoxin levels
• Third-party check
• Proper storage and handling
• Complete records

Safety Tracking Protocol for Research:

Baseline Assessment:

• Medical history and physical review
• Blood pressure and heart rate
• Heart risk assessment
• Skin review (document moles)
• Baseline sexual function questionnaires

During Research:

• Blood pressure tracking (first 3-4 doses)
• Side effect tracking and records
• Sexual function assessments
• Periodic skin examinations (monthly if frequent use)

Follow-Up:

• Post-study assessment of sexual function
• Skin review for pigmentation changes
• Heart parameter check
• Long-term follow-up for any persistent effects

Adverse Event Reporting:

• Document all adverse events, regardless of severity
• Report serious adverse events to institutional review board
• Keep detailed records for control compliance
• Add to post-marketing surveillance if applicable

Summary:

PT-141 has a favorable safety profile supported by FDA approval and extensive clinical trial data. Most side effects are transient and manageable. The main safety concerns are:

1. Transient blood pressure rise (contraindicated in uncontrolled hypertension)
2. Nausea (common but usually tolerable)
3. Rare skin hyperpigmentation with frequent use
4. Very rare priapism risk

Proper patient selection, appropriate dosing, and vigilant tracking minimize risks and ensure safe research conduct.

Quality Assurance: Third-Party Testing and Purity Verification

Research integrity depends fundamentally on peptide quality. Impure, degraded, or incorrectly synthesized peptides produce unreliable results, waste research resources, and possibly compromise subject safety. PrymaLab’s rigorous quality assurance program ensures every PT-141 vial meets pharmaceutical-grade standards matching FDA-approved Vyleesi.

Third-Party Laboratory Testing:

Every batch of PrymaLab PT-141 undergoes full test by independent, ISO-certified laboratories. This third-party check provides unbiased confirmation of quality, removing possible conflicts of interest inherent in vendor self-testing.

High-Performance Liquid Chromatography (HPLC):

HPLC represents the gold standard for peptide purity test:

• Method: Separates peptide components based on chemical properties
• Precision: Quantifies target peptide and identifies impurities
• PrymaLab Standard: ≥99% purity by HPLC
• Interpretation: 99% or more of material is correct PT-141 peptide
• Impurities: <1% consists of minor synthesis byproducts, salts, residual solvents at safe levels

Mass Spectrometry (MS):

Mass spectrometry confirms cell-level identity:

• Purpose: Verifies cell-level weight and amino acid sequence
• Precision: Detects even single amino acid substitutions
• PrymaLab Check: Confirms cell-level weight of 1025.2 g/mol
• Quality Control: Ensures peptide is authentic PT-141, not related compound or synthesis error

Amino Acid Test:

Quantitative amino acid test provides more check:

• Method: Confirms correct amino acid makeup and ratios
• Purpose: Validates peptide identity and sequence
• Quality Assurance: Detects any amino acid substitutions or deletions

Endotoxin Testing:

Bacterial endotoxins can contaminate peptides during synthesis or handling:

• Method: Limulus Amebocyte Lysate (LAL) assay
• PrymaLab Standard: <1 EU/mg (well below FDA limit of 5 EU/mg for injectables)
• Importance: Prevents fever, swelling, and other adverse effects
• Testing Frequency: Every batch tested before release

Sterility Testing:

While freeze-dried peptides are not sterile products, contamination testing ensures safety:

• Method: Tests for bacterial and fungal contamination
• Purpose: Ensures product safety
• Protection: Mixing with sterile water provides antimicrobial protection during storage

Certificate of Test (COA):

Every PrymaLab PT-141 buy includes full records:

COA Contents:

1. Batch number and manufacturing date
2. HPLC purity results with chromatogram
3. Mass spectrometry data confirming cell-level weight
4. Amino acid test results
5. Endotoxin test results
6. Sterility test results
7. Storage recommendations
8. Expiration date
9. Handling instructions

Storage and Shelf life:

Proper storage keeps peptide quality throughout shelf life:

Freeze-dried Powder:

• Heat: -20°C (freezer)
• Duration: Up to 2 years
• Protection: Keep away from light and moisture
• Packaging: Sealed vials with desiccant

Mixed Solution:

• Heat: 2-8°C (refrigerator)
• Duration: Up to 30 days
• Protection: Keep away from light
• Sterility: Use sterile technique to prevent contamination
• Shelf life: Track for cloudiness or discoloration

Handling Best Practices:

• Avoid repeated freeze-thaw cycles
• Use aseptic technique when handling
• Do not shake vigorously (gentle swirling only)
• Protect from direct sunlight
• Store in original packaging until use

Visual Inspection:

Before use, inspect peptide vials for quality indicators:

Freeze-dried Powder Should Be:

• White to off-white color
• Fluffy or cake-like texture
• Free from discoloration
• No clumping or unusual appearance

Mixed Solution Should Be:

• Clear and colorless
• Free from particulates
• No cloudiness or precipitation
• No unusual odor

If Any Abnormalities Saw:

• Do not use the product
• Contact vendor immediately
• Document appearance with photos if possible
• Request replacement

Comparison to Commercial Vyleesi:

PrymaLab PT-141 meets or exceeds the quality standards of FDA-approved Vyleesi:

• Purity: 99%+ (matches pharmaceutical grade)
• Testing: Same analytical methods (HPLC, MS)
• Endotoxins: <1 EU/mg (same as Vyleesi specification)
• Cell-level Weight: 1025.2 g/mol (identical)
• Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 (identical)

Quality Assurance Process:

Step 1: Synthesis

• Pharmaceutical-grade synthesis facility
• GMP-compliant manufacturing
• Batch records and traceability

Step 2: In-House Testing

• First purity assessment
• Identity check
• Preliminary quality control

Step 3: Third-Party Check

• Independent laboratory testing
• HPLC, MS, amino acid test
• Endotoxin and sterility testing

Step 4: Records

• Certificate of Test preparation
• Batch record compilation
• Quality release approval

Step 5: Storage and Shipping

• Proper storage conditions kept
• Cold chain care for shipping
• Packaging to protect from damage

Step 6: Customer Support

• COA provided with every order
• Technical support available
• Replacement policy for quality issues

Control Compliance:

PrymaLab keeps compliance with applicable regulations:

• GMP Standards: Good Manufacturing Practices followed
• ISO Certification: Third-party labs are ISO-certified
• Records: Complete batch records kept
• Traceability: Full chain of custody records
• Research Use: Clearly labeled for research purposes only

Why Quality Matters:

Research Integrity:

• Reliable, reproducible results
• Valid scientific conclusions
• Publishable data

Subject Safety:

• Minimizes contamination risks
• Reduces adverse event possible
• Ensures predictable effects

Cost Effectiveness:

• Avoids wasted research resources
• Prevents need to repeat studies
• Maximizes research investment

Professional Reputation:

• Keeps institutional credibility
• Supports grant uses
• Lets collaboration

Purchasing Considerations: Why Choose PrymaLab

The research peptide market contains many vendors with varying quality standards, customer service, and reliability. Selecting a trusted supplier is crucial for research success. Here’s why PrymaLab stands out as the premier choice for PT-141 (Bremelanotide) research.

Uncompromising Quality Standards:

PrymaLab keeps pharmaceutical-grade quality standards matching FDA-approved Vyleesi:

• 99%+ Purity: Exceeds industry norms, verified by HPLC
• Third-Party Testing: Independent laboratory check
• Complete Records: COA with every order
• Batch Consistency: Rigorous quality control ensures consistency
• FDA-Equivalent Standards: Same quality as approved medication

Transparent Testing Records:

We provide complete transparency in quality check:

• Detailed COAs: HPLC chromatograms, mass spectrometry data, endotoxin results
• Batch Traceability: Full records from synthesis to supply
• Independent Check: Unbiased third-party testing
• Accessible Support: Technical team available to discuss testing data
• Institutional Compliance: Records meets research institution requirements

Competitive Pricing:

Despite premium quality standards, PrymaLab offers exceptional value:

• PT-141 10mg: $45 per vial (competitive vs $60-90 elsewhere)
• Volume Discounts: Available for larger orders
• No Hidden Fees: Transparent pricing structure
• Value Proposition: Pharmaceutical-grade quality at research-grade prices
• Cost Per Dose: About $7.88 per 1.75mg dose (10mg vial = 5.7 doses)

Fast, Reliable Shipping:

Research timelines are key, and we deliver:

• Processing Time: Orders ship within 24 hours of payment
• Domestic Supply: 3-5 business days (USA)
• International Shipping: Available to most countries
• Tracking: Provided for all orders
• Packaging: Discreet, professional packaging
• Cold Chain: Proper heat control kept

Secure Payment Options:

Multiple payment methods for convenience and security:

• Credit Cards: Visa, Mastercard, American Express
• Cryptocurrency: Bitcoin, Ethereum (more privacy)
• Bank Transfers: Wire transfer for larger orders
• Digital Platforms: Zelle, CashApp
• Security: SSL encryption protects all transactions
• Privacy: Discreet billing descriptors

Exceptional Customer Support:

Our knowledgeable team provides full support:

• Response Time: Within 24 hours (often much faster)
• Supply: Email, phone, live chat
• Expertise: Staff trained in peptide research uses
• Technical Support: Help with mixing, dosing, protocols
• Order Tracking: Help with shipping questions
• Problem Resolution: Dedicated to customer satisfaction

Educational Resources:

PrymaLab provides full educational content:

• Detailed Product Descriptions: Research uses and mechanisms
• Dosing Protocols: Evidence-based rules from clinical trials
• Mixing Guides: Step-by-step instructions with images
• Safety Data: Side effect care and tracking
• Research Literature: References to published studies
• Comparison Guides: PT-141 vs other peptides

Institutional Accounts:

We work with research institutions worldwide:

• Volume Pricing: Discounts for institutional orders
• Buy Orders: PO payment options available
• Dedicated Account Care: Personalized service
• Priority Shipping: Expedited supply for institutions
• Custom Records: Tailored to institutional requirements
• Compliance Support: Help with control records

Satisfaction Guarantee:

We stand behind our products with confidence:

• Quality Guarantee: If product doesn’t meet specifications, we’ll replace it
• Response Time: Quality concerns addressed within 24 hours
• Resolution Process: Fair, transparent problem-solving
• Customer First: Your satisfaction is our priority
• Long-term Relationships: We value ongoing partnerships

Control Compliance:

All PrymaLab peptides comply with applicable regulations:

• Research Use Only: Clearly labeled and documented
• Not for Human Consumption: Explicit disclaimers
• Age Check: 21+ requirement enforced
• Professional Use: Intended for qualified researchers
• Records: Proper records kept
• Legal Compliance: Adherence to federal and state laws

Comparison to Other Vendors:

PrymaLab Benefits:

• Pharmaceutical-grade purity (99%+) vs industry average (95-98%)
• Complete third-party testing vs vendor self-testing
• Transparent COAs vs limited records
• Competitive pricing vs premium pricing elsewhere
• Fast shipping vs delayed processing
• Responsive support vs limited supply

Red Flags to Avoid:

• Vendors without third-party testing
• Unusually low prices (may show low purity)
• No COA or limited records
• Poor customer reviews or complaints
• Unclear return/replacement policies
• Lack of professional presentation

Why Researchers Choose PrymaLab:

“I’ve tried several peptide vendors, and PrymaLab consistently delivers the highest quality. The COAs are detailed, shipping is fast, and customer service is excellent.” – University Research Lab

“For PT-141 research, quality is non-negotiable. PrymaLab’s pharmaceutical-grade purity gives me confidence in my results.” – Sexual Medicine Clinic

“The mix of quality, pricing, and support makes PrymaLab my go-to source for all peptide research.” – Independent Researcher

Ordering Process:

Step 1: Browse PT-141 product page Step 2: Select quantity (volume discounts available) Step 3: Add to cart and proceed to checkout Step 4: Choose payment method and complete order Step 5: Get order confirmation and tracking Step 6: Product ships within 24 hours Step 7: Get package with COA included

Customer Support Contact:

• Email: support@prymalab.net
• Phone: Available during business hours
• Live Chat: Real-time help on website
• Response Time: Within 24 hours guaranteed

Related Research Peptides and Supplies

Full peptide research often needs multiple compounds and supplies. PrymaLab offers a complete range of research peptides and essential materials to support your work.

Related Sexual Function Peptides:

Melanotan 2 10mg:

• Parent compound of PT-141
• Broader melanocortin receptor start
• Produces both tanning and sexual effects
• Research uses: Skin pigmentation, sexual function, appetite control
• Comparison: MT-2 has more tanning effect, PT-141 more selective for sexual function

Growth Hormone Peptides for Sexual Health:

Ipamorelin 5mg:

• Selective GH secretagogue
• Improves body makeup and vitality
• May enhance sexual confidence through improved physique
• Combines well with PT-141 for full sexual health

Sermorelin 5mg:

• GHRH analog for natural GH rise
• Supports energy, vitality, and overall wellness
• May improve sexual function indirectly through enhanced vitality
• Excellent adjunct to PT-141 for aging populations

CJC-1295 5mg:

• Long-acting GHRH analog
• Sustained GH rise
• Improves body makeup and energy
• Combined with PT-141 for sexual health research

Tesamorelin 5mg:

• Specialized GHRH analog
• Targets visceral adipose tissue
• FDA-approved mechanism for lipodystrophy
• May improve sexual confidence through body makeup changes

Tissue Repair and Healing Peptides:

BPC-157 5mg:

• Gastric peptide with notable healing properties
• Promotes tissue repair and nerve regrowth
• May benefit post-surgical sexual function healing
• Combines well with PT-141 for pelvic injury rehabilitation

TB-500 5mg:

• Thymosin beta-4 fragment
• Promotes angiogenesis and tissue repair
• May enhance vascular health supporting erectile function
• Combined with PT-141 for vascular ED research

Other Growth Hormone Peptides:

GHRP-6 5mg:

• Potent GH secretagogue
• Appetite boost effects
• May improve overall vitality
• Research uses in aging and wellness

GHRP-2 5mg:

• Strong GH secretagogue
• Bulk building focus
• Improves body makeup
• May enhance sexual confidence

Hexarelin 5mg:

• Most potent GH secretagogue
• Cardioprotective effects
• Brain-safe properties
• Research uses in full health tuning

Essential Research Supplies:

Sterile Water 3mL:

• Sterile water with 0.9% benzyl alcohol
• Essential for peptide mixing
• Provides antimicrobial protection during storage
• Multiple vials recommended for frequent use

Insulin Syringes:

• 0.5mL and 1mL syringes with 29-31 gauge needles
• Precise dosing for peptide use
• Minimal discomfort with small needles
• Proper disposal in sharps container needed

Alcohol Prep Pads:

• Sterile alcohol swabs
• For injection site preparation
• For vial sterilization
• Essential for keeping sterile technique

Sterile Empty Vials:

• For dividing peptide solutions
• For preparing custom forms
• For storing mixed peptides
• Keeps sterility and organization

Research Tools:

Peptide Calculator:

• Free online dosing calculator
• Calculates peptide doses and mixing volumes
• Converts between units (mg, mcg, IU)
• Removes dosing errors
• Simplifies protocol planning

Browse Complete Catalog:

Shop All Peptides:

• Complete range of research peptides
• Organized by category and use
• Detailed product descriptions
• Competitive pricing
• Volume discounts available

Product Categories:

• Sexual Function Peptides
• Growth Hormone Peptides
• Healing and Healing Peptides
• Body Peptides
• Cognitive Boost Peptides
• Anti-Aging Peptides

Frequently Asked Questions (FAQs)

1. What is PT-141 (Bremelanotide) and how does it work?

PT-141, also known as bremelanotide or Vyleesi, is a synthetic melanocortin receptor agonist peptide that enhances sexual function through central nervous system pathways. Unlike traditional erectile dysfunction drugs that work peripherally on blood vessels, PT-141 starts melanocortin receptors (very MC4R) in the hypothalamus, triggering dopamine release in brain regions that govern sexual desire and arousal. This central mechanism starts sexual arousal and erections through the body’s natural pathways, making PT-141 effective for both erectile dysfunction and low libido in men and women. The peptide got FDA approval in 2019 as Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.

2. How does PT-141 differ from Melanotan 2?

PT-141 is a refined metabolite of Melanotan 2, optimized mainly for sexual function boost. Key differences: (1) Control status – PT-141 has FDA approval (as Vyleesi); MT-2 is research-only. (2) Main effects – PT-141 is selective for sexual function with minimal tanning; MT-2 produces both tanning and sexual effects. (3) Receptor selectivity – PT-141 shows higher selectivity for MC4R (sexual function); MT-2 starts MC1R, MC3R, MC4R more equally. (4) Safety profile – PT-141 has lower heart effects and better-characterized safety from FDA trials. (5) Dosing – PT-141 standard dose is 1.75mg; MT-2 ranges from 0.25-2mg. For researchers mainly interested in sexual function without tanning effects, PT-141 is the superior choice.

3. What is the proper dosage for PT-141 research?

The FDA-approved dose is 1.75mg under-skin injection, gave 30-45 minutes before expected sexual activity. Maximum frequency is one dose per 24 hours, no more than 8 doses per month. For a 10mg vial mixed with 2mL sterile water, the 1.75mg dose equals 0.35mL or 35 units on a 100-unit insulin syringe. Effects often onset within 30-60 minutes, peak at 1-2 hours, and last 6-12 hours. Some researchers use slightly lower doses (1.5mg) first to assess tolerance, or higher doses (2.0mg) for enhanced effects, though these are off-label. Always start at the lower end of the dosing range and titrate based on response and tolerability.

4. How do I reconstitute and store PT-141?

Reconstitute by adding 2mL sterile water to the 10mg vial. Inject water slowly against the vial wall, then gently swirl (don’t shake) to dissolve. Refrigerate for 2-4 hours until completely dissolved. Store freeze-dried powder at -20°C (freezer) for up to 2 years. Store mixed solution at 2-8°C (refrigerator) for up to 30 days. Protect from light and avoid repeated freeze-thaw cycles. Use sterile technique when handling to prevent contamination. Before use, inspect the solution – it should be clear and colorless with no particles or cloudiness.

5. What are the most common side effects of PT-141?

The most common side effects are nausea (40%), flushing (20%), and headache (11-12%). Nausea often occurs 30-60 minutes post-injection and lasts 1-4 hours, often diminishing with repeated use. About 13% need anti-emetic medication. Other effects include injection site reactions (5%), spontaneous erections in men (13%), and transient blood pressure increase (+2-3 mmHg systolic). Rare but notable effects include skin hyperpigmentation (1% with frequent use) and very rare priapism. Most side effects are transient and manageable through dose adjustment, timing tuning, and supportive measures like anti-nausea medication and hydration.

6. Can PT-141 be combined with Viagra or Cialis?

Yes, PT-141 can be safely combined with PDE5 inhibitors like Viagra (sildenafil) or Cialis (tadalafil), and research shows powerful synergy. Clinical studies show that combining PT-141 with sildenafil increases erectile activity duration by 5.3-fold compared to sildenafil alone. The mix works because PT-141 starts arousal centrally through the brain while PDE5 inhibitors enhance blood flow peripherally. This addresses both psychological and vascular components of erectile dysfunction. Protocol: Give both 45-60 minutes before sexual activity (PT-141 1.75mg under-skin + sildenafil 50-100mg oral). Track blood pressure closely, especially with first few uses. Ongoing Phase 2 trials are testing co-formulated mixes for possible FDA approval.

7. How long does it take to see results from PT-141?

PT-141 works relatively quickly with effects beginning within 30-60 minutes of under-skin injection. Peak effects occur at 1-2 hours post-injection, when sexual arousal and erectile function are often strongest. The duration of enhanced sexual responsiveness lasts 6-12 hours, though some users report mild residual effects up to 24 hours. Unlike daily drugs, PT-141 is used on-demand before sexual activity. For research assessing overall effectiveness, allow 4-8 doses over 2-3 months to fully assess response, as some subjects report improved effects with repeated use as tolerance to side effects develops.

8. Is PT-141 safe for long-term research?

PT-141 has favorable long-term safety data from FDA approval trials extending up to 12 months. Studies show no buildup of heart effects with ongoing use – blood pressure and heart rate effects remain transient with each dose. No evidence of tissue changes or organ toxicity emerged during trials. However, most research uses PT-141 as-needed (not daily), limiting long-term exposure. Safety factors for extended use include: (1) Limit to recommended maximum of 8 doses per month, (2) Track blood pressure periodically, (3) Watch for skin hyperpigmentation with frequent use, (4) Periodic dermatological review if using >6 months, (5) Consider periodic washout periods (1-2 weeks every 3 months) for very frequent users.

9. What makes PrymaLab’s PT-141 superior to competitors?

PrymaLab PT-141 offers: (1) Pharmaceutical-grade 99%+ purity matching FDA-approved Vyleesi, verified by third-party testing, (2) Complete Certificates of Test with every order including HPLC, mass spectrometry, and endotoxin data, (3) Competitive pricing at $45 per 10mg vial (vs $60-90 elsewhere), (4) Fast shipping within 24 hours of payment, (5) Multiple secure payment options, (6) Exceptional customer support responding within 24 hours, (7) Full educational resources and evidence-based dosing protocols, (8) Satisfaction guarantee and quality commitment. Our rigorous quality standards ensure researchers work with the same quality as FDA-approved medication, providing confidence in research results.

10. Who should not use PT-141 in research?

Exclude subjects with: Uncontrolled hypertension (BP >140/90), heart disease (recent heart attack/stroke, unstable angina, severe heart failure), pregnancy or breastfeeding, age <18 years, history of melanoma or multiple atypical moles, and known hypersensitivity to bremelanotide. Use caution in subjects with well-controlled hypertension (close tracking needed), history of priapism, concurrent use of multiple vasoactive drugs, and severe renal or hepatic impairment. Always screen subjects carefully, use appropriate tracking protocols, and ensure heart health is enough before starting PT-141 research. The FDA approval provides extensive safety data supporting use in appropriate populations under medical supervision.

---

6. TECHNICAL SPECIFICATIONS

Chemical Information

• Chemical Name: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
• Generic Name: Bremelanotide
• Brand Name: Vyleesi (FDA-approved)
• Common Names: PT-141, PT 141, Peptide 141
• Cell-level Formula: C50H68N14O10
• Cell-level Weight: 1025.2 g/mol
• CAS Number: 189691-06-3
• UNII: 6Y24O4F92S
• Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
• Structure Type: Cyclic heptapeptide
• Purity: ≥99% (HPLC verified)
• Appearance: White to off-white freeze-dried powder
• Solubility: Soluble in sterile water, sterile water, or saline

Pharmacological Properties

• Drug Class: Melanocortin receptor agonist
• Main Target: MC4R (Melanocortin-4 Receptor)
• Second Targets: MC1R, MC3R, MC5R
• Mechanism: Central nervous system start of sexual arousal pathways
• Uptake: 100% (under-skin injection)
• Tmax: 1.0 hour (0.5-1.0 hours)
• Half-Life: 2.7 hours (1.9-4.0 hours)
• Duration of Action: 6-12 hours
• Body function: Peptide hydrolysis (no hepatic body function)
• Excretion: 64.8% urine, 22.8% feces

Storage and Handling

• Storage Heat (Freeze-dried): -20°C (freezer)
• Storage Heat (Mixed): 2-8°C (refrigerator)
• Shelf Life (Freeze-dried): 24 months when stored properly
• Shelf Life (Mixed): 30 days when refrigerated
• Light Response: Protect from direct light
• Handling: Use sterile technique; avoid repeated freeze-thaw cycles

Quality Control

• Manufacturing Standard: GMP-compliant facility
• Purity Testing: HPLC, Mass Spectrometry, Amino Acid Test
• Endotoxin Level: <1 EU/mg (LAL assay)
• Sterility: Tested for bacterial and fungal contamination
• Heavy Metals: Below detection limits
• Residual Solvents: Within ICH rules
• Batch Records: Complete traceability

Packaging

• Vial Size: 10mg per vial
• Vial Type: Sterile glass vial with rubber stopper and flip-off cap
• Packaging: Personal vials in protective packaging
• Labeling: Batch number, manufacturing date, expiration date
• Records: Certificate of Test included

Regulatory Status

• FDA Status: Approved as Vyleesi for female HSDD (June 2019)
• Research Use: Available for research purposes
• DEA Schedule: Not a controlled substance
• International: Varies by country; check local regulations

---

7. COMPLIANCE & LEGAL DISCLAIMER

Research Use Only

PT-141 (Bremelanotide) is sold exclusively as a research chemical for scientific and educational purposes. This product is NOT intended for human consumption, medical use, or any use involving use to humans or animals outside of controlled research settings. While PT-141 has FDA approval as Vyleesi for female hypoactive sexual desire disorder, this research-grade form is intended solely for laboratory research.

Age Restriction

Purchasers must be 21 years of age or older. By buying this product, you confirm that you meet this age requirement and will use the product only for legitimate research purposes.

Professional Use

This product is intended for use by qualified researchers, scientists, and healthcare professionals conducting legitimate research. Proper training in peptide handling, mixing, and research protocols is needed.

Not a Medication

PT-141 (Bremelanotide) research peptide is not a medication, drug, or treatment agent for personal use. While the FDA has approved bremelanotide as Vyleesi for specific medical signs, this research-grade product has not been assessed or approved for the treatment, cure, or prevention of any disease or medical condition. Any statements about research uses are based on published scientific literature and do not constitute medical claims.

FDA Approval Context

PT-141 (bremelanotide) got FDA approval in June 2019 as Vyleesi for treating got, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This approval validates the peptide’s mechanism of action and safety profile through rigorous Phase 3 clinical trials. However, the research-grade PT-141 offered by PrymaLab is intended for research purposes only and is not the FDA-approved Vyleesi form for medical use.

Off-Label Research

While PT-141 is FDA-approved for female HSDD, research uses in male populations for erectile dysfunction and low libido represent off-label use. Such research is legitimate and supported by clinical evidence, but researchers must get appropriate institutional approvals and informed consent for human subject research.

Safety and Liability

Users assume all responsibility for proper handling, storage, and use of this product. PrymaLab is not liable for any adverse effects, injuries, or damages resulting from improper use, misuse, or use outside of controlled research settings. Researchers must use appropriate safety protocols and get necessary institutional approvals before conducting research.

Consultation Requirement

Anyone considering research involving PT-141 should consult with qualified healthcare professionals, institutional review boards, and control authorities as appropriate. This is very important for research involving human subjects, which needs proper ethical approval and informed consent procedures.

International Regulations

Peptide regulations vary by country. International purchasers are responsible for ensuring compliance with their local laws and regulations about peptide importation and research use. PrymaLab is not responsible for shipments seized by customs or violations of local regulations.

Product Disclaimer

While we keep rigorous quality control standards, PrymaLab makes no warranties about the suitability of this product for any specific research use. Researchers are responsible for validating product performance in their specific experimental systems.

Medical Disclaimer

This product and the data provided are not intended to diagnose, treat, cure, or prevent any disease. Do not use this product if you are pregnant, nursing, or have any medical condition. Consult a healthcare professional before using any research peptide. The data provided is for educational and research purposes only.

---

8. REFERENCES AND SCIENTIFIC LITERATURE

1. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102.
2. Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000;12 Suppl 4:S74-S79.
3. Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide starts erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393.
4. Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo-controlled study. J Urol. 2008;179(3):1066-1071.
5. Goldstein I, Goldstein S. Use of Bremelanotide (Vyleesi) in Men with Sexual Dysfunctions: Results from a Sexual Medicine Clinic. J Sex Med. 2024;21(Supplement_1).
6. Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial. Womens Health (Lond). 2016;12(3):325-337.
7. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
8. Edinoff AN, Sanders NM, Lewis KB, et al. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurol Int. 2022;14(1):75-88.
9. Clayton AH, Lucas J, DeRogatis LR, Jordan R. Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants. Clin Ther. 2017;39(3):514-526.e14.
10. Both S. Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder. Curr Sex Health Rep. 2017;9(4):192-199.
11. Ückert S, Bannowsky A, Albrecht K, Kuczyk MA. Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies. Expert Opin Investig Drugs. 2014;23(11):1477-1483.
12. King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H. Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem. 2007;7(11):1098-1106.
13. Hadley ME. Discovery that a melanocortin regulates sexual functions in male and female humans. Peptides. 2005;26(10):1687-1689.
14. Rössler AS, Pfaus JG, Kia HK, et al. The melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat. Pharmacol Biochem Behav. 2006;85(3):514-521.
15. FDA. Vyleesi (bremelanotide) Prescribing Data. June 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
16. Palatin Technologies. Press Release: Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Gave with a PDE5i for the Treatment of Erectile Dysfunction. June 2024.

---

9. RELATED PRODUCTS & INTERNAL LINKS

Complementary Sexual Function Peptides

• Melanotan 2 10mg – Parent compound with broader melanocortin start
• Melanotan 1 10mg – Selective MC1R agonist for tanning research

Growth Hormone Peptides for Sexual Health

• Ipamorelin 5mg – Selective GH secretagogue for vitality
• Sermorelin 5mg – GHRH analog for natural GH rise
• CJC-1295 5mg – Long-acting GHRH for sustained benefits
• Tesamorelin 5mg – Specialized GHRH for body makeup
• GHRP-6 5mg – Potent GH secretagogue
• GHRP-2 5mg – Strong GH secretagogue
• Hexarelin 5mg – Most potent GH secretagogue

Recovery and Tissue Repair Peptides

• BPC-157 5mg – Tissue repair and nerve regrowth
• TB-500 5mg – Angiogenesis and vascular health

Essential Research Supplies

• Sterile Water 3mL – For peptide mixing
• Peptide Calculator – Free dosing calculator tool

Browse by Category

• Shop All Peptides – Complete peptide catalog
• Anti-swelling Peptides – KPV, BPC-157, and related compounds
• Growth Hormone Peptides – GHRHs and secretagogues
• Healing Peptides – BPC-157, TB-500, and healing peptides